The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Observational Follow‐Up Study: Benefits of RAS Blockade With Olmesartan Treatment Are Sustained After Study Discontinuation

BACKGROUND: The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study showed that 40 mg Olmesartan medoxomil (OM) versus placebo delayed microalbuminuria onset in patients with type 2 diabetes and normoalbuminuria. METHODS AND RESULTS: One thousand seven hundred and fifty‐ei...

Descripción completa

Detalles Bibliográficos
Autores principales: Menne, Jan, Ritz, Eberhard, Ruilope, Luis M., Chatzikyrkou, Christos, Viberti, Giancarlo, Haller, Hermann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187490/
https://www.ncbi.nlm.nih.gov/pubmed/24772521
http://dx.doi.org/10.1161/JAHA.114.000810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4187490/
https://www.ncbi.nlm.nih.gov/pubmed/24772521
http://dx.doi.org/10.1161/JAHA.114.000810

Ejemplares similares